Back

Emergency Department-Initiated Buprenorphine for Opioid Use Disorder

11:00am - June 30, 2022 thru 12:30pm - June 30, 2022 | Timezone: US/Pacific
Pacific Southwest ATTC
Registration Deadline: June 30, 2022

 

Webinar Banner

 

Presenter Gail D'Onofrio Headshot. Red hair and black jacket.

 

This webinar, presented by Gail D'Onofrio, MD, will focus on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. The opioid epidemic combined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with rising rates of fentanyl use. Dr. D'Onofrio will share data supporting the use of buprenorphine in the ED and discuss the consequences of not initiating treatment, barriers to implementation of ED buprenorphine, and components of successful integration of an ED program with community partnerships. She will also share current research by emergency physicians regarding innovative strategies like high-dose induction and use of an extended release 7-day formulation of buprenorphine.

 

Learning objectives

  • Evaluate at least 2 outcomes for opioid use disorder in patients receiving buprenorphine through the Emergency Department and discuss supporting evidence
  • Identify at least 2 barriers and 2 solutions to initiating buprenorphine in the Emergency Department
  • Apply at least 2 harm reduction strategies and components of the buprenorphine integration pathway
  • Propose at least 2 innovative solutions for buprenorphine induction in the ED including different formulations of buprenorphine and high dose strategies

 

Sponsored by the Northwest and Pacific Southwest Addiction Technology Transfer Centers (ATTCs) and the Western States Node of the NIDA Clinical Trials Network.

 

1.5 CME or CE credits available. See credit types below.

Accreditation

In support of improving patient care, this activity has been planned and implemented by Stanford Medicine and the Northwest Addiction Technology Transfer Center (ATTC). Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)

Stanford Medicine designates this Live Activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

Stanford Medicine designates this internet live activity for a maximum of 1.5 ANCC contact hours.

American Psychological Association (APA)

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibly for the content of the programs.

 

CE Accreditation

This webinar meets the qualifications for the provision of one and one-half (1.5) continuing education credits/contact hours (CEs/ CEHs). UCLA ISAP is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for

LMFTs, LCSWs, LPCCs, and/or LEPs (Provider #64812). UCLA ISAP maintains responsibility for this program/course and its content.

Course meets the qualifications for one and one-half (1.5) hours of continuing education credit for LMFTs, LCSWs, LPCCs, and LEPs as required by the California Board of Behavioral Sciences. UCLA ISAP is also an approved provider of continuing education for RADTs I/II, CADCs-CASs, CADCs I/II, CADCs-CSs, and LAADCs (CCAPP, #2N- 00-445-1123), CATCs (ACCBC/CAADE, #CP40 872 C 0822), and

CAODCs (CADTP, #151). CE credit will be awarded at the conclusion of the webinar. Partial credit will not be available for those participants who arrive late or leave early.